Skip to Content
Search Menu

Neoadjuvant melanoma: ESMO 2025 updates in 2 minutes

Associate Professor Marco Donia, MD, PhD, University of Copenhagen and Clinician-Scientist at Herlev Hospital, reviews the latest long-term data from ESMO 2025, highlighting why neoadjuvant treatment may outperform adjuvant therapy, and exploring emerging biomarkers and strategies.
Marco Donia

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Teresa Macarulla

ESMO 2025: HER2-Targeted Therapy Advances in BTC

/ Teresa Macarulla
ESMO25NBCN Play the Video 4:06

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

/ Jan Andreasen
ESMO25Prostate cancer

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

/ Jan Andreasen
Bladder cancerESMO25
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lung cancer Play the Video 05:43

Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

/ Igle Jan de Jong / Jan Andreasen
ESMO25

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
Breast cancerESMO25NBCN
John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
Breast cancerESMO25NBCN Play the Video 03:24
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
Breast cancerESMO25NBCN Play the Video 05:53
Jakob Lauritsen

ESMO 2025: Interesting New Data on the Treatment of Bladder Cancer

/ Jakob Lauritsen
Bladder cancerESMO25 Play the Video 03:47
Back to top